CAS NO: | 330834-54-3 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | AGX51 is a first-in-class pan-Id(inhibitors of DNA-binding/differentiation proteins) antagonist and degrader. AGX51 inhibits theId1-E47interaction, leading to ubiquitin-mediated degradation of Ids, cell growth arrest, and reduces viability. AGX51 inhibits the TNBC cell lines withIC50s of nearly 25 μM. AGX51 can be used for the research ofcancer[1]. | ||||||||||||||||||||||||||||||||||||||||||||||||
IC50& Target | IC50: 26.66 μM (4T1), 8.7 μM (HMLE RAS Twist), 22.28 μM (MDA-MB-157), 30.91 μM (MDA-MB-436), 36.55 μM (SK-BR-3), 60 μM (MCF-7), 10.89 μM (PDX-BR7), 11.97 μM (PDX-IBT) , 18.56 μM (PDX-BR11)[1] | ||||||||||||||||||||||||||||||||||||||||||||||||
体外研究 (In Vitro) | AGX51 (0-80 μM; 24 h) decreases ID1 protein levels in 4T1 cells[1].AGX51 (40 μM; 0-72 h) decreases ID1 levels protein with a 40 μM concentratio in 4T1 cells[1].AGX51 (40 μM; 24 h) influences 4T1 cells , ER+, HER2+, TNBC and three breast cancer PDX cell ines[1].AGX51 (0-80 μM; 24-48 h) influences cell cycle of 4T1 cells[1].AGX51 (40 μM; 4-24 h) influences phospho-histone H3 levels in 4T1 cells[1].AGX51 (40 μM; 24 h) influences ROS levels in 4T1 cells[1]. Western Blot Analysis[1]
Western Blot Analysis[1]
Cell Viability Assay[1]
Cell Cycle Analysis[1]
Cell Viability Assay[1]
Cell Viability Assay[1]
| ||||||||||||||||||||||||||||||||||||||||||||||||
体内研究 (In Vivo) | AGX51 (50 mg/kg; i.p. twice a day for 4 weeks) inhibits lung metastasis[1].AGX51 (15 mg/kg; i.p. twice a day for 3 weeks) exibits anti-tumor activity with autochronous cancer[1].
| ||||||||||||||||||||||||||||||||||||||||||||||||
分子量 | 431.52 | ||||||||||||||||||||||||||||||||||||||||||||||||
性状 | Oil | ||||||||||||||||||||||||||||||||||||||||||||||||
Formula | C27H29NO4 | ||||||||||||||||||||||||||||||||||||||||||||||||
CAS 号 | 330834-54-3 | ||||||||||||||||||||||||||||||||||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||||||||||||||||||||||||||||||||||
储存方式 |
| ||||||||||||||||||||||||||||||||||||||||||||||||
溶解性数据 | In Vitro: DMSO : 100 mg/mL(231.74 mM;Need ultrasonic) Ethanol : 100 mg/mL(231.74 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|